Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. (OTCQB: BETRF) is an emerging biotechnology company whose news flow centers on the development of its proprietary non-hallucinogenic compounds for neuro-psychiatric and neurological disorders. Company announcements highlight scientific data, intellectual property milestones, corporate developments and financing-related transactions tied to its lead assets BETR-001 and BETR-002.
News releases frequently cover scientific and clinical pathway updates, such as preclinical results on BETR-001’s neuroplastogenic activity, mechanistic data on serotonin receptor engagement, and progress through IND-enabling studies. BetterLife also reports on regulatory interactions, including pre-IND meetings with the FDA, and outlines its expectations for future IND filings and potential human trials, as described in its own communications.
Another recurring theme in BetterLife’s news is intellectual property and partnering activity. The company has announced the grant of a composition of matter patent for BETR-001 by the USPTO and references earlier synthesis patents on 2-bromo-LSD. It also issues updates on strategic engagements, such as its agreement with Shanghai-based YAFO Capital to pursue partnering opportunities for BETR-001 in the Greater China region and participation in international life sciences and investment forums.
Investors and observers will also find corporate and capital markets updates, including board and advisory appointments, debt settlements and conversions into equity, and commentary on management share ownership and regulatory matters. Together, these news items provide a view into how BetterLife is advancing its pipeline, managing its capital structure and positioning its non-hallucinogenic neuroplastogens within the broader neuro-psychiatric treatment landscape, based on the company’s own disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced that its collaborators from Carleton University will present findings on BETR-001, a non-hallucinogenic LSD derivative, at the SOBP Conference, April 27-29, 2023, in San Diego. Preclinical data indicate that BETR-001 enhances stress-coping behaviors and reverses anxiety and depression in mouse models, correlating with increased neuroplasticity in the prefrontal cortex. Driven by the serotonin 5-HT2A receptor, these effects position BETR-001 as a promising candidate for treating mood disorders without the regulatory challenges of traditional psychedelics. CEO Ahmad Doroudian noted that ongoing IND-enabling studies will pave the way for human trials. BetterLife's proprietary patents protect BETR-001, facilitating potential self-administration and broader patient access.
BetterLife Pharma Inc., a biotechnology company focused on mental disorder treatments, announced that its CEO Dr. Ahmad Doroudian and COO Dr. Hooshmand Sheshbaradaran will present at the Bloom Burton Healthcare Investor Conference on April 26, 2023, in Toronto.
This prominent event invites leading public and promising private companies in the healthcare sector to connect with global investors. Attendees can expect presentations and one-on-one meetings.
BetterLife is advancing two compounds, BETR-001 and BETR-002, targeting neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic LSD derivative, while BETR-002 is based on honokiol from magnolia bark.
For registration details, visit the Bloom Burton website.
BetterLife Pharma Inc. has announced the publication of an article on its lead candidate BETR-001 (2-bromo-LSD), highlighting its potential for treating depression without hallucinations. The article, featured in Drug Discovery & Development, elaborates on BETR-001's positive preclinical data and safety profile compared to LSD, developed in partnership with notable scientists. The company is advancing BETR-001 towards human clinical trials post-IND-enabling studies. BetterLife also develops other compounds for neuro-psychiatric and neurological disorders, including BETR-002. The management emphasizes the significant therapeutic potential of BETR-001 in neuro-psychiatric conditions.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced on March 22, 2023, that Medical Xpress published an article discussing its lead candidate, BETR-001 (2-bromo-LSD), aimed at treating mood disorders. The article describes the positive data from the pharmacological characterization of BETR-001, conducted with renowned scientists. CEO Ahmad Doroudian highlighted BETR-001's therapeutic potential and improved safety profile compared to LSD, with human clinical trials projected to commence after IND-enabling studies. BetterLife is focused on developing innovative treatments for neuro-psychiatric disorders, including BETR-002, based on honokiol.